Learn about an MS treatment option

6 Monate vor

Text only:

An invitation to learn more.

A Message From Our Sponsor

Provided by

An invitation to treat MS differently.
View Web & Mobile Version
Call 1-844-OCREVUS (1-844-627-3887)
OCREVUS® (ocrelizumab) is the first and only FDA approved treatment for both relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
Select safety information
Infusion reactions: OCREVUS can cause infusion reactions that can be serious and require you to be hospitalized.
Want to learn more about OCREVUS?
Receive information about OCREVUS, along with additional resources that may be helpful throughout the course of your treatment.
*REBIF® is a registered trademark of EMD Serono, Inc.
†Disability progression was measured using a tool called the Expanded Disability Status Scale (EDSS). Disability progression was confirmed 3 months after the initial neurological worsening.
‡Disability progression was also confirmed after 6 months.
What is OCREVUS?
OCREVUS is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis.
It is not known if OCREVUS is safe or effective in children.
Important Safety Information
Who should not receive OCREVUS?
Do not receive OCREVUS if you have an active hepatitis B virus (HBV) infection.
Do not receive OCREVUS if you have had a life threatening allergic reaction to OCREVUS. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or any of its ingredients in the past.
What is the most important information I should know about OCREVUS?
OCREVUS can cause serious side effects, including:

Infusion reactions: OCREVUS can cause infusion reactions that can be serious and require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms:

itchy skin




coughing or wheezing

trouble breathing

throat irritation or pain

feeling faint


redness on your face (flushing)



swelling of the throat


shortness of breath


fast heart beat
Important Safety Information continued below.
What is the most important information I should know about OCREVUS? (continued)
These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion.
If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.


OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or signs of herpes (such as cold sores, shingles, or genital sores). These signs can happen during treatment or after you have received your last dose of OCREVUS. If you have an active infection, your healthcare provider should delay your treatment with OCREVUS until your infection is gone.

Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with OCREVUS treatment in clinical trials, PML may happen with OCREVUS. PML is a rare brain infection that usually leads to death or severe disability. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.

Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS.

Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
Before receiving OCREVUS, tell your healthcare provider about all of your medical conditions, including if you:

have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS.

have ever had hepatitis B or are a carrier of the hepatitis B virus.

have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required vaccines at least 6 weeks before you start treatment with OCREVUS. You should not receive certain vaccines (called ‘live’ or ‘live attenuated’ vaccines) while you are being treated with OCREVUS and until your healthcare provider tells you that your immune system is no longer weakened.

are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and for 6 months after your last infusion of OCREVUS.

are breastfeeding or plan to breastfeed. It is not known if OCREVUS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS.
What are the possible side effects of OCREVUS?
OCREVUS may cause serious side effects, including:

Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer.
Most common side effects include infusion reactions and infections.
These are not all the possible side effects of OCREVUS.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
For more information, go to www.OCREVUS.com or call 1-844-627-3887.
For additional safety information, please see the full Prescribing Information and Medication Guide.
Privacy Policy | Terms & Conditions | Contact Us
Unsubscribe to stop receiving emails from Genentech.
This email is intended for U.S. residents only.
© 2018 Genentech USA, Inc. All rights reserved. OCR/022818/0047
Genentech USA, Inc.
1 DNA Way
South San Francisco, CA 94080-4990

This promotional email is brought to you by Genentech.

You are receiving this e-mail because you have requested to receive content, special promotions and offers on behalf of our advertisers when you registered. If you would like to unsubscribe, click here.

Remove me from this list |
Manage my email settings |
Customer Service

Copyright ©
2018 Everyday Health, Inc. All rights reserved.

345 Hudson Street, 16th Floor, New York, NY 10014
Subject to our terms of service and our privacy policy.

If you believe this has been sent to you in error, please safely unsubscribe.


Kategorien: Gesundheit | Wohlfahrt
Alter: 7 - 13 Jahr 14 - 18 Jahr 19 - 30 Jahr 31 - 64 Jahre 65 Jahre und älter

Teilen Sie diesen Newsletter

© 2019